There is growing clinical evidence in support of a diet for irritable bowel syndrome (IBS) that is low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP). This low FODMAP diet is gaining acceptance globally among clinicians and IBS sufferers alike. However, there is disparity concerning the success rates of the FODMAP diet between patients, which can be attributed to differences in the recommended diet itself and to adherence issues. To address the differences in the diet, a generally accepted science-based definition of the analytical criteria for low FODMAP products suitable for a low FODMAP diet should be developed. To address the adherence challenge, regulators should permit manufacturers of low FODMAP products to communicate the benefits of a low FODMAP diet on product labels and promotional material which will facilitate people with IBS' selection and use low FODMAP foods.
Introduction
Irritable bowel syndrome is a common functional gastrointestinal disorder that affects approximately 10% to 20% of the general adult population in Europe and in America. 1 Diet modification has generally been considered to be supportive as some foods are common triggers of IBS symptoms. 2 In recent years, the benefits of a low FODMAP diet in controlling IBS symptoms has been supported by increasing clinical evidence [3] [4] [5] and has been endorsed by medical and scientific organizations as well as patient associations. [6] [7] [8] [9] However, the success and use of the low FODMAP diet outside selected institutions has been limited, partly due to the challenges in the use of the diet, which has led to poor adherence and unsatisfactory results. According to the review article by Nanayakkara et al., the "limitations of low FODMAP diet include lack of clear cutoff levels for FODMAP content in foods and nonavailability of information on FODMAP content on food packages."
5 While improved dietitian support and educational tools, such as low FODMAP mobile phone applications, are being used to address the educational challenges, there are some fundamental scientific and regulatory points that must be solved to optimize the way low FODMAP products can be developed and used to facilitate a low FODMAP diet. This review aims to address these scientific points, that is, the need for clear definitions and standardized analytical criteria as well as the necessary regulatory frameworks that would allow appropriate communication on low FODMAP diets and products to be made. By developing consensus and awareness of what constitute low FODMAP diets and its benefits, health care professionals and people with IBS will be able to select and use the right products to help manage IBS symptoms.
Need for globally accepted analytical criteria for low FODMAP products
The identification of the FODMAP content on the label of processed foods, a major component of the Western diet, based solely on its list of ingredients may not be accurate due to the presence of unlabeled substrates or alteration in FODMAP content arising from the processing of the food product. Firstly, validated methods of analysis to establish the FODMAP content of a finished food product must be developed. Secondly, generally accepted levels for (i) fermentable oligosaccharides; (ii) disaccharides; (iii) monosaccharides; and (iv) polyols should be defined for qualifying a product as being "low FODMAP." These levels must be based upon the evidence of beneficial effects in people with IBS.
While Monash University in Australia has developed a series of analytical criteria for low FODMAP products, 10 there is a need for a global recognition of the methodology and the development of analytical laboratories that can analyze the products in other geographies.
Need for a regulatory framework that allows communication of low FODMAP foods to people with IBS Low FODMAP products suitable for a low FODMAP diet would fall under the general food category in most countries' jurisdictions. They would typically meet the food/dietary supplement classification criterion only if they are presented in a concentrated presentation such as powders, tablets, or capsules. [11] [12] [13] However, most jurisdictions prohibit general food and food or dietary supplement products from communicating health benefits to populations with a disease or medical conditions such as IBS and strictly limit such communication to drug products.
In most countries, there is a regulatory category in between general foods and drugs, that is, foods for special medical purpose or the US equivalent medical foods, which can be labelled for the dietary management of a medical condition. Yet, low FODMAP products do not comply with one of the legal criteria of the foods for special medical purpose/medical foods category, that is, that the dietary management of the disease or medical condition (in this case IBS) can be achieved by a modification of the normal diet alone. [14] [15] [16] Need for endorsement of low FODMAP products by third-party institutions and the need for approved nutrition and health claims
In most countries, it is permitted for products to carry on their label endorsements by medical or scientific organizations such as "certified/ or recognized by the organization x," if the product complies with local requirements on such endorsements. 17, 18 For example in Australia, if a product is analyzed for its FODMAP levels at Monash University and if the results fulfill the Monash criteria of low FODMAP products, a logo with the statement "Monash University low FODMAP certified" can be displayed on the product. 10 In other countries, such science-based low FODMAP certification schemes should be established as well. Such science-based certification schemes would provide the basis for both endorsements by medical and scientific organizations and acceptance by regulators worldwide.
Nutrition claims such as "low in FODMAP" and health claims such as "A low FODMAP diet helps to improve gut comfort in subjects with digestive sensitivities" should also be authorized and incorporated in positive lists when those exist (e.g. Europe and Brazil). This would be possible with a continuous clinical research effort and engagement with the authorities.
Favorable regulatory frameworks would allow manufacturers to label and communicate clearly the low FODMAP characteristics and benefits of their products and facilitate for consumers the adherence to a low FODMAP diet.
Conclusions
The low FODMAP diet has gained acceptance in the global medical and scientific community as a non-pharmacological pillar of IBS management. However, the implementation of the diet remains challenging for many. For manufacturers of low FODMAP food products aimed at facilitating a low FODMAP diet, there are a number of hurdles that limit the ability to adequately communicate the health benefits of such products. To address this, a scientific consensus on systematic methods to analyze the FODMAP content and clear cut-off values to qualify the product as "low FODMAP" should be reached. Subsequently, regulators should be engaged to accept the science-based low FODMAP criteria. In addition, manufacturers should partner with academic institutes for clinical research to deepen the understanding of the low FODMAP diet in IBS with particular focus on its long-term use and benefits in different types of IBS. In parallel, the development of optimal education tools for healthcare professionals and people with IBS should be continued as a cornerstone for the wider and more successful use of the low FODMAP diet.
